Inogen, Inc. (INGN)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$7.10+0.85%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Inogen, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	83.99M
EPS	—	-0.175
FY 2026 · Annual
Revenue	$355M–$361M	356.42M
EPS	—	-0.764
FY 2027 · Annual
Revenue	—	372.58M
EPS	—	-0.477

What the Thesis Depends On

5 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain gross profit near $38M per quarter	Gross profit remains stable near $38 million per quarter.	Intact	gross profit falls below $35M per quarter	Gross profit: $43.272M FY2026-Q2; GAAP. Published target: gross profit >= $35M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 7, 202643,272,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 92906140-ee82-44bc-8f06-ef458a3c7931. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Strengthen executive team with new COO and CFO	The company is improving leadership with new COO and CFO hires.	Intact	no operational improvements or leadership turnover within 12 months	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q3 with the appointment of Andy Reding as COO. This leadership addition aims to support revenue growth and operational performance. No direct financial metrics yet, so delivery is early and pending further updates. Delivery assessment Oct 24, 2026
Improve operating income from negative $9.3M in 2026-Q1	A primary condition in Inogen, Inc.'s published investment case. The stated target is operating income better than -$9.3M in next 4 quarters.	Under Pressure	operating income remains at or below -$9.3M in next 4 quarters	Operating income: $-5.096M FY2026-Q2; GAAP. Published target: operating income better than -$9.3M in next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 7, 2026-5,096,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 92906140-ee82-44bc-8f06-ef458a3c7931. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve ~6% revenue growth to ~$370M in FY26	A primary condition in Inogen, Inc.'s published investment case. The stated target is ~$370M revenue in FY26.	Improving	revenue falls below $349M in FY26	Revenue: $95.084M FY2026-Q2; GAAP. Published target: ~$370M revenue in FY26. Target period ends 2026-12-31; this observation covers 2026-Q2. Source published Aug 7, 202695,084,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 92906140-ee82-44bc-8f06-ef458a3c7931. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $92.3 million in 2025-Q2 to $95.1 million in 2026-Q2 (3.0% growth). Full-year 2026 revenue guidance is $355 million to $361 million, reflecting about 3% growth at midpoint versus 2025. The trajectory is delivering consistent growth aligned with management's stated target. Delivery assessment Oct 24, 2026
Execute $30M share repurchase program	It has a $30 million share buyback program to support the stock.	Intact	no meaningful repurchases executed by end 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. The Company repurchased 1,145,150 shares for $7.5 million in first half 2026 under the $30 million program. In September 2026, the Board increased the authorization to $45 million. The program is actively executed and expanded, matching management's stated capital return focus. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 3
2026-07-25	Unavailable	Unavailable	1 / 3
2026-07-26	Unavailable	Unavailable	1 / 3
2026-07-27	Unavailable	Unavailable	1 / 2
2026-07-28	Unavailable	Unavailable	1 / 3
2026-07-29	Unavailable	Unavailable	1 / 3
2026-07-30	Unavailable	Unavailable	1 / 3
2026-07-31	Unavailable	Unavailable	1 / 3
2026-08-01	Unavailable	Unavailable	1 / 2
2026-08-02	Unavailable	Unavailable	1 / 2
2026-08-03	Unavailable	Unavailable	1 / 3
2026-08-04	Unavailable	Unavailable	1 / 3
2026-08-05	Unavailable	Unavailable	1 / 3
2026-08-06	Unavailable	Unavailable	1 / 3
2026-08-07	Unavailable	Unavailable	1 / 2
2026-08-08	Unavailable	Unavailable	1 / 3
2026-08-09	Unavailable	Unavailable	1 / 3
2026-08-10	Unavailable	Unavailable	1 / 2
2026-08-12	Unavailable	Unavailable	1 / 3
2026-08-13	Unavailable	Unavailable	1 / 2
2026-08-14	Unavailable	Unavailable	1 / 2
2026-08-15	Unavailable	Unavailable	1 / 2
2026-08-16	Unavailable	Unavailable	1 / 2
2026-08-17	Unavailable	Unavailable	1 / 2
2026-08-18	Unavailable	Unavailable	1 / 2
2026-08-19	Unavailable	Unavailable	1 / 2
2026-08-20	Unavailable	Unavailable	1 / 2
2026-08-21	Unavailable	Unavailable	1 / 2
2026-08-22	Unavailable	Unavailable	1 / 2
2026-08-23	Unavailable	Unavailable	1 / 2
2026-08-24	Unavailable	Unavailable	1 / 2
2026-08-25	Unavailable	Unavailable	1 / 2
2026-08-26	Unavailable	Unavailable	1 / 2
2026-08-27	Unavailable	Unavailable	1 / 2
2026-08-28	Unavailable	Unavailable	1 / 2
2026-08-29	Unavailable	Unavailable	1 / 2
2026-08-30	Unavailable	Unavailable	1 / 2
2026-08-31	Unavailable	Unavailable	1 / 2
2026-09-01	Unavailable	Unavailable	1 / 2
2026-09-02	Unavailable	Unavailable	1 / 1
2026-09-03	Unavailable	Unavailable	1 / 1
2026-09-04	Unavailable	Unavailable	1 / 1
2026-09-05	Unavailable	Unavailable	1 / 1
2026-09-06	Unavailable	Unavailable	1 / 1
2026-09-07	Unavailable	Unavailable	1 / 1
2026-09-08	Unavailable	Unavailable	1 / 1
2026-09-09	Unavailable	Unavailable	1 / 1
2026-09-10	Unavailable	Unavailable	1 / 1
2026-09-11	Unavailable	Unavailable	1 / 1
2026-09-12	Unavailable	Unavailable	1 / 1
2026-09-13	Unavailable	Unavailable	1 / 1
2026-09-14	Unavailable	Unavailable	1 / 1
2026-09-15	Unavailable	Unavailable	1 / 1
2026-09-16	Unavailable	Unavailable	1 / 1
2026-09-17	Unavailable	Unavailable	1 / 1
2026-09-18	Unavailable	Unavailable	1 / 1
2026-09-19	Unavailable	Unavailable	1 / 1
2026-09-20	Unavailable	Unavailable	1 / 1
2026-09-21	Unavailable	Unavailable	1 / 1
2026-09-22	Unavailable	Unavailable	1 / 1
2026-09-23	Unavailable	Unavailable	1 / 1
2026-09-24	Unavailable	Unavailable	1 / 1
2026-09-25	Unavailable	Unavailable	1 / 1
2026-09-26	Unavailable	Unavailable	1 / 1
2026-09-27	Unavailable	Unavailable	1 / 1
2026-09-28	Unavailable	Unavailable	1 / 1
2026-09-29	Unavailable	Unavailable	1 / 1
2026-09-30	Unavailable	Unavailable	1 / 1
2026-10-01	Unavailable	Unavailable	1 / 1
2026-10-02	Unavailable	Unavailable	1 / 1
2026-10-03	Unavailable	Unavailable	1 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1
2026-10-17	Unavailable	Unavailable	1 / 1
2026-10-18	Unavailable	Unavailable	1 / 1
2026-10-19	Unavailable	Unavailable	1 / 1
2026-10-20	Unavailable	Unavailable	1 / 1
2026-10-21	Unavailable	Unavailable	1 / 1
2026-10-22	Unavailable	Unavailable	1 / 1
2026-10-23	Unavailable	Unavailable	1 / 1
2026-10-24	Unavailable	Unavailable	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	3	0	0
2026-08-01	3	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain gross profit near $38M per quarterGross profit: $43.272M
Strengthen executive team with new COO and CFOQualitative condition
Improve operating income from negative $9.3M in 2026-Q1Published status: Under Pressure
Achieve ~6% revenue growth to ~$370M in FY26Revenue: $95.084M
Execute $30M share repurchase programDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

5 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-43.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Inogen, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a smaller-cap healthcare business with a gradual-growth and profitability-improvement thesis, rather than a proven durable compounder. The long-term thesis is intact, but fragile earnings quality and elevated risk make execution important.

What's priced into Inogen, Inc.

The valuation evidence points to INGN being cheap versus peers, with a low-confidence model and an expectations gap that suggests limited expectations are reflected. The priced-in assessment is marked justified, not broadly fragile, though that does not remove the business risks.

What the fundamentals likely do

Near term, management is on track with its 2026 priorities: about 3% revenue growth, higher adjusted EBITDA, and international expansion. Q2 revenue grew 3.0% year over year, international revenue grew 14.8%, and adjusted EBITDA increased, though the company remains loss-making. A guidance reversal after the recent raise, or weaker employment data, could add pressure to an already elevated-risk setup.

What Inogen, Inc. hinges on

Over the next 1 to 3 years, the thesis hinges on sustaining modest revenue growth while improving profitability and expanding internationally. A guidance cut after the recent raise would damage management credibility; continued strong results from healthcare peers could support the sector backdrop. Evidence on the recent agreement and announced share buybacks is limited in this snapshot.